A number of tools are available to assess disease severity and progression in patients with peripheral neuropathies such as CIDP. Gain a better understanding of four of these tools.
IgG Levels and Wear Off Reflect Administration and Outcome
Carol L. Koski, MD
GBS/CIDP Foundation International
5:51 MIN
CIDP
GBS
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
Duke University Medical Center in Durham, North Carolina
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
CIDP
Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.
Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
CIDP
MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
MMN
Jonathan S. Katz, MD, is the Director, Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California.
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
CIDP
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.